Stocks Health care CRSP
NASDAQ · Health careCRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG brought in $25.2M of revenue over the twelve months to September 30, 2026, down 34.3% from a year earlier. It posted a net loss of $456.1M. In fiscal 2025 capital spending exceeded operating cash flow by $345.9M. At September 30, 2026 it held $192M in cash against $586.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 2, 2026.
Key facts about CRISPR Therapeutics AG
- Net worth
- CRISPR Therapeutics AG has a market value (market cap) of $4.9B at the latest share price, and shareholders' equity of $1.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3.5M (-90.6% year on year), with a net loss of $581.6M. Over the 12 months to September 30, 2026: revenue $25.2M, net loss $456.1M.
- Cash flow
- In fiscal 2025 operations used $345M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 2, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- CRISPR Therapeutics AG's next report is expected around February 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What CRISPR Therapeutics AG does
CRISPR Therapeutics AG is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRSP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.5M | -$581.6M | -$6.47 | -$345.9M |
| 2024 | $37.3M | -$366.3M | -$4.34 | -$144.7M |
| 2023 | $371.2M | -$153.6M | -$1.94 | -$269.8M |
| 2022 | $1.2M | -$650.2M | -$8.36 | -$532.9M |
| 2021 | $915M | $377.7M | $4.70 | $457.3M |
| 2020 | $719K | -$348.9M | -$5.29 | -$256.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CRSP ranks in Health care
Latest SEC filings
What CRISPR Therapeutics AG has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 1,325% to $12.7M versus the same quarter last year; diluted EPS -$1.15 versus -$1.17.
- November 2, 2026
- October 19, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 1,041% to $10.2M versus the same quarter last year; diluted EPS -$0.94 versus -$2.40.
- August 3, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- June 5, 2026
- June 4, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running CRISPR Therapeutics AG did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $4.9M worth of shares in the last 90 days and bought none on the open market. 30% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 19, 2026 | Kulkarni SamarthChief Executive Officer, Director | Sold | 47,837 | $2.4M |
| October 16, 2026 | Kulkarni SamarthChief Executive Officer, Director | Exercised options | 100,000 | - |
| October 14, 2026 | George SimeonDirector | Exercised options | 30,000 | $420K |
| October 14, 2026 | George SimeonDirector | Soldpre-planned (10b5-1) | 14,514 | $720.4K |
| October 14, 2026 | Kulkarni SamarthChief Executive Officer, Director | Sold | 4,098 | $201.9K |
| October 14, 2026 | Kasinger James R.General Counsel and Secretary | Sold | 1,040 | $51.2K |
| October 13, 2026 | Kulkarni SamarthChief Executive Officer, Director | Exercised options | 8,333 | - |
| October 13, 2026 | Kasinger James R.General Counsel and Secretary | Exercised options | 2,113 | - |
Who owns CRSP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| ARK Investment Management LLC13G, passive with 1 related filers | 11.79% | April 30, 2026 |
| Orbis Investment Management Ltd13G, passive with 1 related filers | 5.6% | August 14, 2026 |
| Capital World Investors13G, passive | 5.1% | May 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 522 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| ARK Investment Management LLC | 9,460,939 | -1,852,684 |
| BlackRock, Inc. | 8,348,977 | +668,904 |
| Orbis Allan Gray Ltd | 5,449,161 | -656,850 |
| Capital World Investors | 4,749,525 | +24,488 |
| State Street Corp | 4,321,666 | +339,166 |
| GSK plc | 3,220,627 | 0 |
| Geode Capital Management, LLC | 2,509,915 | +132,751 |
| SR One Capital Management, LP | 2,038,763 | 0 |
| Two Sigma Investments, LP | 1,988,621 | +505,570 |
| Fmr LLC | 1,908,503 | -46,191 |
| Sumitomo Mitsui Trust Group, Inc. | 1,720,734 | -133,141 |
| Amova Asset Management Americas, Inc. | 1,720,097 | -133,778 |
| EcoR1 Capital, LLC | 1,389,276 | 0 |
| UBS Group AG | 1,317,499 | -445,031 |
| Capital International Investors | 1,268,407 | +81,613 |
| Vanguard Capital Management LLC | 1,181,847 | +39,304 |
| Bank of America Corp | 1,155,105 | +172,033 |
| NEA Management Company, LLC | 1,058,570 | 0 |
| Charles Schwab Investment Management Inc | 1,057,837 | +18,488 |
| D. E. Shaw & Co., Inc. | 893,812 | new |
Insiders
6 insiders reported holding 474,080 shares in total, about $24M at the last price.
| Holder | Shares |
|---|---|
| Kulkarni SamarthChief Executive Officer, Director | 311,899 |
| Kasinger James R.General Counsel and Secretary | 95,857 |
| Patel NaimishChief Medical Officer | 19,357 |
| Behbahani AliDirector | 16,66629 held indirectly |
| George SimeonDirector | 15,486 |
| Prasad RajuChief Financial Officer | 14,815 |
Questions about CRSP
What does CRISPR Therapeutics AG do?
CRISPR Therapeutics AG is a company in the Health care sector, listed on NASDAQ as CRSP. Its shares trade on NASDAQ under the ticker CRSP.
What is CRISPR Therapeutics AG's net worth?
CRISPR Therapeutics AG has a market value (market cap) of $4.9B at the latest share price, and shareholders' equity of $1.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is CRISPR Therapeutics AG profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $456.1M on revenue of $25.2M.
How much revenue does CRISPR Therapeutics AG make?
Over the twelve months to September 30, 2026 CRISPR Therapeutics AG reported revenue of $25.2M. That is 34.3% less than a year earlier.
When did CRISPR Therapeutics AG last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 2, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the planned insider sale from November 6, 2026.
When is CRISPR Therapeutics AG's next earnings report?
CRISPR Therapeutics AG's next report is expected around February 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CRSP with
Follow CRSP
Get an email when CRISPR Therapeutics AG files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values CRISPR Therapeutics AG tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.